LRRC32 and neoplasm: In our TNBC model, GARP expression was likely too low to show an efficient GARP-targeted TRT treatment, but it could also be used to improve current immunotherapies as suggested by recent findings demonstrating that low-dose TRT may render immunologically cold tumours responsive to immune checkpoint blockade [62].